BACKGROUND: Pazopanib is an oral tyrosine kinase inhibitor with demonstrated efficacy and tolerability in patients with advanced renal cell carcinoma (RCC).
• The few U.S. studies of treatment patterns with oral, targeted anticancer agents in patients with advanced renal cell carcinoma (RCC) mostly reported results of patients receiving sunitinib or sorafenib.
• The tyrosine kinase inhibitor pazopanib was approved by the FDA in 2009 for treatment of patients with advanced RCC, but there is little information available on patient persistence and adherence outside of clinical trials.
What is already known about this subject
• Given the importance that oral cancer therapies play in specialty care, this study adds to the gap in the literature regarding persistence/compliance with oral oncolytics outside of the clinical trial setting.
• Drug utilization and treatment patterns among patients who received pazopanib as treatment for advanced RCC outside the clinical trial setting showed that more than one-half of patients were on pazopanib for almost 4 months and were both persistent and compliant.
What this study adds
to start of pazopanib therapy was 104.7 (± 199.3) days in the first-line cohort and 360.9 (± 187.0) days in previously treated patients (P = 0.001). Forty-six patients switched to another therapy: 17 patients in the first-line cohort and 29 patients in the previously treated cohort; the mean (± SD) time to switching therapy from each cohort was 94.7 (± 41.4) days and 87.8 (± 49.6) days (P = 0.146), respectively. Statistically significant differences were observed for the starting and ending doses between the 2 cohorts. The average daily dosage of pazopanib was > 700 mg in both cohorts (P = 0.055), with a maximum dose of 800 mg. Random forest models demonstrated that younger age and higher comorbidity predicted both higher persistence and compliance.
CONCLUSIONS: In this observational study, > 50% of patients with advanced RCC were on pazopanib for almost 4 months, with the majority of both cohorts achieving high persistence and high compliance. Additionally, younger age and higher comorbidity index were the strongest predictors of both greater persistence and compliance. Further studies with larger cohorts and longer follow-up are needed to validate these findings.
prescription drug experience) and Truven Health MarketScan Medicare Supplemental and Coordination of Benefits Database (includes health care experience of individuals with employerpaid Medicare supplemental insurance). 13 For this study, the claims covered dates of service between October 1, 2007 
Study Sample Selection
Eligible patients required evidence of receipt of pazopanib by at least 1 claim for pazopanib (NDC: 0173-0804-09) between October 1, 2009, and September 30, 2011. The date of the first pharmacy claim for pazopanib during this period was set as the index date. Evidence of advanced RCC was also required, demonstrated by at least 2 claims with a primary diagnosis for RCC (ICD-9-CM: 189.0, 189.1) at least 30 days apart and within 2 years prior to the index date and at least 1 claim with a diagnosis of metastatic disease (ICD-9-CM: 196.xx-199.xx). At least 1 primary RCC diagnosis code must have appeared prior to or on the same date as the claim with the metastatic RCC diagnosis. Patients who were continuously enrolled in the health plan for at least 60 days prior to the index date and for at least 180 days after the index date and who were aged at least 18 years on the index date were selected for further analysis. The study used a 1-year pre-index period to define patient baseline characteristics. The postperiod was defined as 180 days post-index date and was used to assess all study measures listed in Table 1 .
Two patient cohorts were defined: (1) treatment-naïve pazopanib users who had no evidence of therapies used to treat advanced RCC between their metastatic diagnosis date and the index date (first-line cohort), and (2) pazopanib users with a history of treatment with ≥ 1 other therapies prior to initiating pazopanib (previously treated cohort). I n 2013, it was estimated that kidney cancer would account for approximately 3% to 5% of all cancers in the United States, with 65,150 new cases and 13,680 deaths expected. 1, 2 Until 2005, cytokine therapy had been the only approved standard initial therapy for treating advanced renal cell carcinoma (RCC) postsurgery. These treatments are associated with high toxicities and offer limited clinical benefit to selected patients. 3, 4 Recent therapeutic advances have led to novel targeted therapies for patients with advanced RCC, which include mammalian target of rapamycin inhibitors, the monoclonal antibody bevacizumab, and tyrosine kinase inhibitors (TKIs). 4 Pazopanib (Votrient), approved by the U.S. Food and Drug Administration in October 2009, is an orally available, multitargeted TKI that has demonstrated efficacy and acceptable tolerability in 2 phase lll clinical trials of advanced/metastatic RCC. 5, 6 Pazopanib is dosed continuously as 800 milligrams (mg; four 200 mg tablets) once daily. 7 There has been an increased use of specialty drugs within oncology. 8 Although many of these drugs may come with a high cost, oncologists are more likely to prescribe them over intravenous drug regimens as they pay more attention to patient preferences and quality-of-life issues and to the convenience and flexibility that oral treatment options can provide for patients, while also taking advantage of the availability of specialty pharmacies. However, dosing and adherence to these treatments outside of the clinical trial setting has not been well studied, and may be lower than that in clinical trials. 9 Having a better understanding of such outcomes may help oncologists and payers to make more informed decisions regarding treatment choices and reimbursement of these medicines. [10] [11] [12] The primary objective of the current study was to estimate medication persistence and compliance (adherence) among patients with advanced RCC receiving pazopanib as first-line therapy or after previous treatment with ≥ 1 other therapies outside the clinical trial setting. Secondary objectives were to describe patient characteristics and other treatment and utilization patterns by line of therapy, as well as examine predictors of persistence and compliance among the overall population.
This study used a third-party de-identified database provided by Truven Health MarketScan Research Databases, which contain individual, de-identified health care claims information from employers, health plans, hospitals, Medicare, and Medicaid programs. Used primarily for research, these databases are fully Health Insurance Portability and Accountability Act (HIPAA) compliant. Therefore, this study is exempt from international institutional review board approval.
■■ Methods Data Source
A retrospective, cohort observational study was conducted, utilizing claims data from the Truven Health MarketScan Commercial Claims and Encounters Database (includes employee and dependents' inpatient, outpatient, and outpatient
Persistence and Compliance with Pazopanib in Patients with Advanced
Renal Cell Carcinoma Within a U.S. Administrative Claims Database
Study Measures
There were 12 measures studied, which are defined in Table 1 . Persistence was measured using estimated level of persistence with therapy (ELPT), time to discontinuation, and proportion of days covered (PDC). Compliance was measured using medication possession ratio (MPR). 14, 15 Other treatment and utilization patterns measured included time to initiation of therapy, time to switching to another therapy, average daily dose, initial daily dose (IDD), and ending dose.
Random forests methodology (see Appendix C, available in online article) was used to select predictor variables for both persistence (PDC) and compliance (MPR) models. 16, 17 The predictors included in the models were age, Charlson Comorbidity Index (CCI), plan type, treatment-naïve or first-line, gender (sex), IDD, and commercial versus Medicare population.
Statistical Analysis
All statistical analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC). The random forest models were performed using R 2.15.1 (http://www.r-project.org/). All treatment and utilization variables were analyzed descriptively. Means, medians, standard deviations (SDs), and ranges were provided for continuous variables. Numbers and percentages were provided for categorical variables. PDC and MPR were multiplied by 100 to yield a percentage, set as a dichotomous variable, and categorized as either low or high based on <80% versus ≥ 80%, respectively. Bivariate comparisons between first-line and previously treated patient results were conducted. Appropriate tests (e.g., t-test, Mann Whitney-U test, chi-square test) were used based on the distribution of the measure. The a priori alpha level for relevant analyses was set at 0.05, and all statistical tests were two-tailed, unless otherwise specified. Time-to-event endpoints were analyzed using Kaplan-Meier methods.
■■ Results Patient Characteristics
A total of 143 patients (62 first-line and 81 previously treated) met all inclusion criteria (Figure 1 ). The greatest source of attrition was the requirement for continuous eligibility 60 days pre-index and 6 months post-index (182 patients excluded).
The mean age of all pazopanib users was 62.9 years; 71.3% of users were male; and 55.2% had a PPO-type insurance plan ( Table 2 ). The year of advanced RCC diagnosis was about evenly distributed from 2008 to 2010, with patients having an average of about 1 year since initial RCC diagnosis. Most patients had CCI scores ≥ 7 (90.9%), and 60.8% had hypertension. Among the previously treated cohort (n = 81), 40 were previously treated with sunitinib, 32 with everolimus, 19 each with sorafenib and temsirolimus, 8 with bevacizumab, and 4 with interferons. These were not mutually exclusive groups, and patients may have received > 1 of these therapies prior to initiating pazopanib.
Persistence
The duration of time (i.e., number of days) from initiation to discontinuation of therapy. 7 
Estimated level of persistence with therapy (ELPT)
The percentage of individuals remaining on therapy at 30, 60, and 90 days until the run-out date prior to a 30-day gap in therapy. 8 Time to discontinuation of therapy A sufficiently large gap in therapy (30 days) from the time of treatment initiation. The date of discontinuation was defined as the date when the days' supply of the last prescription filled ran out prior to the gap in therapy, plus 15 days. 8 
Covered days
The number of days during the treatment period for which the patient had a supply of pazopanib on hand. Days' supply
The number of days supplied on the most recent prior pazopanib claim minus the number of days elapsed since that claim.
Proportion of days covered (PDC)
The ratio of pazopanib covered days (drug on hand) to the duration of the pazopanib treatment period (number of days). 8 PDC = the ratio of (total days drug available minus days' supply of last prescription) to (last prescription date minus first prescription date). Compliance (adherence)
The extent to which a patient acts in accordance with the prescribed interval and dose of a dosing regimen, 7 measured by medication possession ratio.
Medication possession ratio (MPR)
The proportion of time over the course of a patient's treatment that he/she theoretically was in possession of medication. 8 MPR = the ratio of (the number of total days' supply of pazopanib [not including the last refill]) to (the duration of pazopanib therapy [number of days between first and last fill]). The maximum MPR was 1.0; that is, patients who are perfectly compliant will have MPRs of 1.0, whereas those who are less than fully compliant will have MPRs < 1.0.
Time to initiation of therapy
The number of days from metastatic diagnosis to the first pazopanib claim (index date).
Time to switching to another therapy Among patients who discontinued pazopanib, the number of days to initiation of the new drug. Patients were followed until switching, end of eligibility, or end of study, whichever came first. Average daily dose (without any dose interruptions)
The quantity of medication supplied multiplied by drug strength/days' supply.
Initial daily dosage (IDD) The product of the milligram (mg) per tablet for pazopanib (200 mg) and the prescribed number of pills per days for the index claim. The prescribed number of pills per day was the ratio of the quantity supplied to the days supplied on the index claim.
Ending dose
The average daily dose from the final pazopanib fill prior to discontinuation of pazopanib, switching, end of eligibility, or end of study, whichever occurred first. 
Persistence and Compliance
Continuous pazopanib therapy for up to 90 days was observed in more than 50% of patients in both cohorts (Table 3) . ELPT at 30, 60, and 90 days was similar between the first-line and previously treated cohorts. Two patients (1 from each cohort) discontinued pazopanib therapy within the first 30 days. The patient-persistence curve (Figure 2 ) indicates that at 6 months (180 days), 33% of first-line patients and 38% of previously treated patients were still persistent with pazopanib therapy. The mean and median time to pazopanib discontinuation, or average duration of pazopanib therapy, was also similar in the first-line versus previously treated cohorts (Table 3) . A significantly greater number of patients in the previously treated cohort had high persistence (PDC ≥ 80%) compared with those in the first-line cohort (80.3% vs. 64.5%, respectively; P = 0.034).
Only 126 patients were assessed for MPR because 17 patients did not have at least 2 pazopanib claims within the database needed for the MPR calculation (Table 3) . First-line Final cohort of all pazopanib users during study period N = 143
Treatment-naïve (first-line) 62
Other pazopanib users (previously treated) 81 RCC = renal cell carcinoma. 
FIGURE 1
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Persistence and Compliance with Pazopanib in Patients with Advanced
Renal Cell Carcinoma Within a U.S. Administrative Claims Database and previously treated patients had similar compliance. High compliance (MPR ≥ 80%) was also significantly greater in the previously treated cohort than in the first-line cohort (83.3% vs. 66.7%, respectively; P = 0.029).
Treatment and Utilization Patterns
On average (± SD), there was a 104.7 (± 199.3)-day gap between the time from metastatic diagnosis to start of pazopanib therapy in patients from the first-line cohort versus a 360.9 (± 187.0)-day gap for patients in the previously treated cohort (P = 0.001). Almost all patients in both cohorts (91.9% of firstline and 90.2% of previously treated patients) had at least a 30-day supply of therapy, and 6.5% of first-line and 3.7% of previously treated patients had a 90-day supply ( Table 3 ). The average (± SD) days' supply of pazopanib therapy over 180 days was 125.9 (± 59.8) in the first-line cohort and 131.1 (± 67.3) in the previously treated cohort. Forty-six patients switched to another therapy: 17 patients in the first-line cohort and 29 patients in the previously treated cohort; the mean (± SD) time to switching therapy from each cohort was 94.7 (± 41.4) days and 87.8 (± 49.6) days (P = 0.146), respectively. The average (± SD) daily dose of pazopanib was 763 (± 122) mg in the first-line cohort and 703 (± 220) mg in the previously treated cohort. Additionally, the maximum average daily dose during the entire pazopanib use period was 800 mg in both cohorts. The average (± SD) initial daily dose of pazopanib was 761 (± 130) mg in the first-line cohort and 686 (± 240) mg in the previously treated cohort; this difference was statistically significant (P = 0.028; Table 3 ). The mean (± SD) ending dose of pazopanib was 768 (± 109) mg in the first-line cohort and 686 (± 235) mg in the previously treated cohort, representing a statistically significant difference (P = 0.013). Figure 3 shows the random forest plots with persistence (PDC; Figure 3A -C) and compliance (MPR; Figure 3D -F) as outcomes in the models. Figure 3A and 3D demonstrate how age and CCI most strongly correlated with each outcome (Gini > 8) . The correlations also demonstrate that younger age ( Figure 3B and 3E) and higher CCI ( Figure 3C and 3F) each predicted higher persistence and higher compliance. costs due to increased physician visits, unnecessary diagnostic testing, higher hospitalization rates, longer hospital stays, and changes in dose or regimen. 18 Few studies on persistence and compliance with oral therapies have been conducted in patients with RCC, despite that many therapies to treat this disease are orally available agents. A prospective, multicenter, observational study (Investigating Patient Satisfaction with Oral Anti-cancer Treatment) of patients with advanced RCC is ongoing in Belgium. Preliminary results from this trial suggest high adherence in this patient population. 20 Previous U.S. studies retrospectively assessing treatment patterns of targeted agents used as first-line therapy for RCC have mostly reported results of patients receiving sorafenib (approved in 2005) and sunitinib (approved in 2006), with ■■ Discussion Evidence suggests that routinely assessing adherence and implementing adherence programs can lead to improved health status. 18 While some studies now include adherence assessments, the rates reported in clinical trials may be higher than those observed outside of trials due to biases in assessment of adherence, such as response bias and recall bias in self-reporting, as well as careful patient selection during recruitment and the intense attention paid to those enrolled. The mechanism of action of many oral cancer therapies is cytostatic in nature, such that they are optimally effective when given chronically; therefore, daily oral therapy is required to control the disease. 19 Nonadherence can contribute greatly to the variability observed in a drug's therapeutic effect and may also increase 
Factors Associated with Persistence and Compliance
Persistence and Compliance with Pazopanib in Patients with Advanced Renal Cell Carcinoma Within a U.S. Administrative Claims Database
Further research is needed to better understand the reasons for discontinuation of drug use and nonadherence in these subgroups. The time to initiation of pazopanib treatment from the diagnosis of metastatic disease ranged from 3 months for first-line users to 1 year for patients treated with another firstline therapy prior to pazopanib. Additionally, a small proportion of patients were on therapy for approximately 3 months prior to discontinuation and switching to another therapy. It would be useful to explore the reasons for prescribing patterns and discontinuation and whether they are associated with pazopanib-related AEs.
Limitations
This retrospective analysis used health insurance claims data and is limited to the variables that are included within that data. The data are also subject to coding errors and incomplete claims history and clinical information. Our estimates of persistence and compliance do not account for the possibility that patients acquired prescription medications from pharmacies not included in the database or participated in clinical trials. We also do not confirm actual ingestion of the medication by patients. Post-index factors such as treatment response and AEs were not examined as predictors of persistence and compliance. Finally, although the database is geographically diverse, it is based on a small convenience sample that is not representative of the U.S. population; therefore, the findings may not be generalizable to all populations.
■■ Conclusions
More than one-half of patients with advanced RCC in this study were on pazopanib for almost 4 months and were persistent and compliant. Younger age and higher comorbidity index were the strongest predictors of both greater persistence and compliance with pazopanib therapy. Further studies with larger cohorts and longer follow-up are needed to validate our findings.
small sample sizes limiting assessments of other agents, including pazopanib. [21] [22] [23] [24] A retrospective database study of dosing patterns of first-line sunitinib, dosed once daily on a 4-weeks-on, 2-weeks-off dosing schedule, showed that patients commonly underwent sunitinib dose reductions within the first 3 treatment cycles due to toxicity and discontinued therapy within the first 5 cycles due to progressive disease. 25 Combined, the findings from these studies suggest that a high percentage of patients in routine clinical settings could discontinue treatment with TKIs in < 6 months. [21] [22] [23] [24] These findings are also in contrast with the duration of therapy reported in phase lll trials of sorafenib and sunitinib. 26, 27 These differences may indicate that patient selection or adverse event (AE) management in clinical trials may differ from that in routine practice. Feinberg et al. (2012) assessed treatment patterns from medical records and found that most discontinuations from sunitinib and sorafenib were attributed to disease progression (34% vs. 37%) and AEs (24% vs. 31%). 21 Overall duration of pazopanib therapy observed in this observational study was lower than that observed in clinical trials yet consistent between the first-line and previously treated cohorts. Median treatment duration for patients receiving pazopanib in the pivotal and COMPARZ clinical trials was 7.4 6 and 8.0 months, 5 respectively, whereas the median duration of therapy in this study was almost 4 months (111.5 days in the first-line cohort and 123.0 days in the previously treated cohort). However, continuous pazopanib therapy for up to 90 days was observed in > 50% of patients in both the first-line and previously treated cohorts. In addition, high persistence (PDC ≥ 80%) and high compliance (MPR ≥ 80%) were observed in both cohorts. The average daily pazopanib dose was > 700 mg in both cohorts, with a maximum dose of 800 mg, implying that patients were administered pazopanib according to the recommended dose. 7 However, any dose changes were not assessed in our study due to the short follow-up period. Among various factors, younger age and higher comorbidity both demonstrated the strongest correlations with higher persistence and compliance. Differences in patient population, sample size, methodology, and practice settings among these previous studies and the current study preclude direct comparisons of the results. However, these data indicate the need to better understand the differences in study measures between clinical trial results and those in routine clinical practice. Patient selection, AE management, cost to the patient, and patient preferences are potential areas that should be assessed.
Results of the current study provide implications for future research. While the mean persistence and compliance observed with pazopanib in this study are relatively high, approximately 35% of patients in the first-line cohort and 20% in the previously treated cohort had PDC and MPR < 80%.
